Amsterdam, The Netherlands, November 27, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its Interim Management Statement for the nine months ended 30 September 2015.
Operational review
Kiadis Pharma continued to make good progress in developing its lead product ATIR101TM for blood cancer:
Full enrolment of the ongoing Phase II clinical study (CR-AIR-007) with ATIR101TM has been accomplished. The primary endpoint for the last patient in this trial will be reached at the end of Q1, 2016 and top-line results will follow at the beginning of Q2, 2016.
Another study (CR-AIR-008), testing repeat dose administration of ATIR101TM in parallel with the ongoing Phase II trial, has been initiated and has enrolled its first patient.
Establishing a closed manufacturing process that allows for automation which is advancing according to plan.
Interim financial results
In the first nine months of 2015, the Company did not generate any revenues. The net loss for the nine months ended 30 September 2015 came at a level of €13.1 million. Expenses and net results are in line with management expectations. The Company ended the first nine months of 2015 with €31.3 million in cash and cash equivalents and an equity position of €29.1 million.
Kiadis Pharma listed its shares via an IPO on Euronext Amsterdam and Brussels on 2 July 2015. The gross proceeds from the IPO came to a total of €34.7 million and net proceeds came to a total of €31.2 million.
The financial information in this press release has not been audited nor reviewed by the external auditor.
